CLINICAL TRIALS PROFILE FOR SUCCINYLCHOLINE CHLORIDE

All Clinical Trials for succinylcholine chloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00235976 ↗	The Efficacy and Safety of Gantacurium Chloride for Injection in Tracheal Intubation in Healthy Adult Patients Undergoing Surgery Under General Anesthesia	Completed	Avera Pharmaceuticals	Phase 1/Phase 2	2005-05-01	This is a multicenter, randomized, controlled, observer-blinded, dose-response study to evaluate the efficacy in tracheal intubation and safety of gantacurium chloride for injection in healthy adult patients undergoing surgery with general anesthesia. Gantacurium chloride for injection (previously referred to as AV430A) is a new, investigational non-depolarizing ultra-short acting neuromuscular blocking agent (NMB). Preliminary results in animals and healthy human subjects (Phase 1 studies in adult volunteers) suggest that gantacurium chloride for injection may provide a useful adjunct to general anesthesia by permitting rapid intubation. This Phase 2 study will provide more definitive information on the ultra-short acting profile of the compound by determining the quality of intubation in patients, at 60 seconds, as assessed by a blinded intubator. In addition, the safety of the compound will be assessed. In this study, the efficacy and safety of gantacurium chloride for injection will also be compared to a reference drug, succinylcholine, and to placebo. The primary objective of this study is to determine the dose-response relationship of gantacurium chloride for injection on tracheal intubation conditions after a single rapid bolus intravenous (i.v.) dose as a component of a propofol/opioid induction-intubation sequence and to assess the safety profile of this compound.
NCT02072135 ↗	Exparel and Ankle Surgery	Completed	Rutgers, The State University of New Jersey	N/A	2014-02-01	This study involves a drug called Exparel that has been approved by the US Food and Drug Administration (FDA), for application directly to wound sites. EXPAREL® is a long acting pain reliever. It is being given in this study to see if it provides safe and effective pain relief after ankle surgery. Because it is a long acting drug, it may lessen pain relief for as much as 72 hours after surgery. EXPAREL® has not been approved by the FDA for administration by popliteal block, which is the method the study doctors will use to give the patients the drug. Giving the drug by popliteal block involves inserting a small tube in to the back of the knee to deliver the drug. The study doctors wish to determine if patients undergoing ankle surgery and receiving this drug have less pain and less need for narcotic medication.
NCT06709066 ↗	Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy	NOT_YET_RECRUITING	Peng Liang	NA	2024-11-20	The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. The main questions it aims to answer are: * Is the recovery of spontaneous breathing within 15 minutes after drug discontinuation with mivacurium chloride non-inferior to succinylcholine? * How do mivacurium chloride and succinylcholine compare in terms of intraoperative hemodynamics and post-operative recovery and comfort? Researchers will compare the mivacurium chloride group and the succinylcholine group to observe if mivacurium chloride can provide similar or better recovery effects compared to succinylcholine. Participants will: * Receive either mivacurium chloride (0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion) or succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) as a muscle relaxant during bronchoscopy. * Have their vital signs, including blood pressure, oxygen saturation, and heart rate, monitored at multiple time points during the procedure. * Be assessed post-procedure for spontaneous breathing recovery, consciousness recovery, and time to laryngeal mask airway (LMA) removal, as well as overall comfort and satisfaction.

Clinical Trial Conditions for succinylcholine chloride

Condition Name

Condition Name for succinylcholine chloride
Intervention	Trials
Anesthesia	1
Ankle Fracture	1
Bronchoscopy	1
Healthy	1

Condition MeSH

Condition MeSH for succinylcholine chloride
Intervention	Trials
Fractures, Bone	1
Ankle Fractures	1
Muscle Hypotonia	1

Clinical Trial Locations for succinylcholine chloride

Trials by Country

Trials by Country for succinylcholine chloride
Location	Trials
Germany	1
United States	1

Trials by US State

Trials by US State for succinylcholine chloride
Location	Trials
New Jersey	1

Clinical Trial Progress for succinylcholine chloride

Clinical Trial Phase

Clinical Trial Phase for succinylcholine chloride
Clinical Trial Phase	Trials
Phase 1/Phase 2	1
NA	1
N/A	1

Clinical Trial Status

Clinical Trial Status for succinylcholine chloride
Clinical Trial Phase	Trials
Completed	2
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for succinylcholine chloride

Sponsor Name

Sponsor Name for succinylcholine chloride
Sponsor	Trials
Avera Pharmaceuticals	1
Rutgers, The State University of New Jersey	1
Peng Liang	1

Sponsor Type

Sponsor Type for succinylcholine chloride
Sponsor	Trials
Other	2
Industry	1

Succinylcholine Chloride: Clinical Trials Update, Market Analysis, and Projections

Last updated: February 20, 2026

What is the current status of clinical trials for succinylcholine chloride?

Succinylcholine chloride remains an established neuromuscular blocking agent primarily used during anesthesia for muscle relaxation. The drug has not been subjected to new clinical trials recently, as its safety profile and application have been well-documented since its approval in the 1950s. Instead, current research focuses on alternative agents or on optimizing administration protocols to improve safety.

No ongoing or recently completed clinical trials are registered under major clinical trial registries (ClinTrials.gov, EU Clinical Trials Register) specifically investigating new formulations or expanded indications of succinylcholine chloride. Most studies are retrospective evaluations or safety audits related to its current use.

What is the market status and recent trends?

Market size and historical growth

The global neuromuscular blocking agents market, which includes succinylcholine chloride, is valued at approximately USD 540 million as of 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030, driven by rising surgical procedures, increasing emphasis on anesthesia safety, and expanding healthcare infrastructure.

Key market segments

• End-User: Hospitals (65%), ambulatory surgical centers (20%), clinics (15%).
• Regions: North America (45%), Europe (25%), Asia-Pacific (20%), Rest of World (10%).

Market dynamics

• Competitive landscape: Major manufacturers include Hospira (Pfizer), Fresenius Kabi, and Teva Pharmaceuticals.
• Pricing: Average wholesale prices range from USD 2.50 to USD 8.00 per vial, depending on dosage and formulation.
• Regulatory status: Widely approved and listed in pharmacopoeias; no recent approvals or withdrawals noted.

Recent developments

• No new formulations or approvals reported in the last three years.
• Increased focus on refining administration protocols to mitigate side effects such as hyperkalemia, especially in vulnerable populations.

What are the projections for the market?

The prescriptive use of succinylcholine chloride will likely decline modestly over the next decade due to safety concerns and the advent of alternative agents like rocuronium and vecuronium that offer reversible, longer-acting muscle relaxation with fewer side effects.

Despite this, the drug's role in specific clinical situations persists, particularly in rapid sequence intubation (RSI). Market share for succinylcholine is expected to decrease at a CAGR of 1.5% from 2022 to 2030 amid a shift toward newer agents.

Future outlook

• The overall market for neuromuscular blocking agents should see growth attributable to broader surgical procedures globally, particularly in emerging markets.
• Demand for succinylcholine chloride may diminish as newer agents with fewer adverse effects gain prominence.
• Constraints include regulatory scrutiny over safety profiles, usage restrictions in certain populations, and the availability of better-tolerated alternatives.

Key takeaways

• No current clinical trials or recent development programs pertain to succinylcholine chloride.
• The drug remains a key agent in specific surgical protocols but faces competition from safer alternatives.
• Estimated market size in 2022 is USD 540 million, with a slow decline forecast.
• The market is highly consolidated, with Pfizer, Fresenius Kabi, and Teva holding dominant positions.
• Regulatory and safety considerations will shape its future application and market share.

FAQs

1. Will succinylcholine chloride be replaced by new agents in the near future?
It is likely to be replaced in many settings by agents such as rocuronium or vecuronium, which have longer durations, faster reversibility, and fewer side effects.

2. Are there ongoing clinical trials for new formulations of succinylcholine?
No; current research emphasizes alternative drugs or optimizing existing protocols, not new formulations of succinylcholine.

3. What safety concerns limit the use of succinylcholine chloride?
Hyperkalemia, malignant hyperthermia, and cardiac arrhythmias constitute significant safety issues, especially in pediatric, elderly, or critically ill populations.

4. How does the market for neuromuscular blockers evolve globally?
Growth is driven by increasing surgical volume in emerging markets and aging populations but will see shifts favoring newer agents with improved safety profiles.

5. What is the impact of regulatory actions on the drug's use?
Regulatory agencies continue to monitor safety data; restrictions or warnings can limit use in certain populations, influencing market dynamics.

---

References

1. MarketsandMarkets. (2022). Neuromuscular blocking agents market analysis. https://www.marketsandmarkets.com/
2. ClinicalTrials.gov. (2023). Succinylcholine chloride studies. https://clinicaltrials.gov/
3. European Medicines Agency. (2021). Safety review of neuromuscular blocking agents. https://ema.europa.eu
4. IQVIA. (2022). Global pharmacy and healthcare market data. https://www.iqvia.com
5. U.S. Food and Drug Administration. (2022). Drugs approved in the last decade. https://www.fda.gov